Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, Habib; Maleki, Mina; Sathyapalan, Thozhukat; Jamialahmadi, Tannaz; Sahebkar, Amirhossein
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones. There is emerging evidence that they have anti-inflammatory effects. Since most long-term complications of diabetes have a background of chronic inflammation, these agents may be beneficial against diabetic complications not only due to their hypoglycemic potential but also via their anti-inflammatory effects. However, the exact molecular mechanisms by which GLP-1RAs and DPP-4i exert their anti-inflammatory effects are not clearly understood. In this review, we discuss the potential molecular pathways by which these incretin-based therapies exert their anti-inflammatory effects.
|Journal Article Type||Article|
|Publication Date||Jan 15, 2020|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020). Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sciences, 241, https://doi.org/10.1016/j.lfs.2019.117152|
|Keywords||General Pharmacology, Toxicology and Pharmaceutics; General Biochemistry, Genetics and Molecular Biology; General Medicine; GLP-1 receptor agonist; DPP-4 inhibitor; Diabetes mellitus; Diabetic complication; Inflammation|
|Additional Information||This article is maintained by: Elsevier; Article Title: Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes; Journal Title: Life Sciences; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lfs.2019.117152; Content Type: article; Copyright: © 2019 Elsevier Inc. All rights reserved.|
This file is under embargo due to copyright reasons.
Contact T.Sathyapalan@hull.ac.uk to request a copy for personal use.